| Patent Number |
Title Of Patent |
Date Issued |
| 7351712 |
Pyrimidine derivatives for the treatment of abnormal cell growth |
April 1, 2008 |
| The present invention relates to a compound of the formula 1 ##STR00001## wherein R.sup.1-R.sup.4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using s |
| 7235562 |
Pyrimidine derivatives for the treatment of abnormal cell growth |
June 26, 2007 |
| The present invention relates to a compound of the formula 1 ##STR00001## wherein R.sup.1-R.sup.4 and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method |
| 7208499 |
Pyrimidine derivatives for the treatment of abnormal cell growth |
April 24, 2007 |
| The present invention relates to a compound of the formula 1 ##STR00001## wherein A and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compo |
| 7145008 |
Pyrimidine derivatives for the treatment of abnormal cell growth |
December 5, 2006 |
| The present invention relates to a compound of the formula 1 ##STR00001## or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R.sup.1 R.sup.4 and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell |
| 7122670 |
Selective synthesis of CF3-substituted pyrimidines |
October 17, 2006 |
| The present invention relates to a method of making a compound of the formula ##STR00001## wherein X.sup.1, X.sup.2 and R.sup.3--R.sup.4 are as defined herein. The method includes reacting a compound of the formula ##STR00002## with an amine of formula 3 (HNR.sup.3R.sup.4) in the p |
| 7109337 |
Pyrimidine derivatives for the treatment of abnormal cell growth |
September 19, 2006 |
| The present invention relates to a compound of the formula 1 ##STR00001## wherein R.sup.1 R.sup.4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using suc |
| 7109335 |
Pyrimidine derivatives for the treatment of abnormal cell growth |
September 19, 2006 |
| The present invention relates to a compound of the formula 1 ##STR00001## wherein R.sup.1 R.sup.4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using suc |
| 7105529 |
Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhi |
September 12, 2006 |
| Compounds of formula (I): wherein X is N, CH, CCF.sub.3, or C(C.sub.1-12 aliphatic); R.sup.4 is sulfonic acid, C.sub.1-12 aliphatic-sulfonyl, sulfonyl-C.sub.1-12 aliphatic, C.sub.1-12 aliphatic-sulfonyl-C.sub.1-6 aliphatic, C.sub.1-6 aliphatic-amino, R.sup.7-sulfonyl, R.sup.7 sulfony |
| 6964961 |
Thiophene derivatives useful as anticancer agents |
November 15, 2005 |
| The invention relates to compounds of the formula 1 ##STR1##or a pharmaceutically acceptable salt and to pharmaceutically acceptable salts and hydrates thereof, wherein X, Y, R.sup.1, R.sup.2 and R.sup.11 are as defined herein. The invention also relates to pharmaceutical composition |
| 6541503 |
Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kina |
April 1, 2003 |
| Compounds of formula (I): wherein X is N, CH, CCF.sub.3, or C(C.sub.1-12 aliphatic); R.sup.4 is sulfonic acid, C.sub.1-12 aliphatic-sulfonyl, sulfonyl-C.sub.1-12 aliphatic, C.sub.1-12 aliphatic-sulfonyl-C.sub.1-6 aliphatic, C.sub.1-6 aliphatic-amino, R.sup.7 -sulfonyl, R.sup.7 sulfon |
| 6387919 |
Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kina |
May 14, 2002 |
| Compounds of formula (I): wherein X is N, CH, CCF.sub.3, or C(C.sub.1-12 aliphatic); R.sup.4 is sulfonic acid, C.sub.1-12 aliphatic-sulfonyl, sulfonyl-C.sub.1-12 aliphatic, C.sub.1-12 aliphatic-sulfonyl-C.sub.1-6 aliphatic, C.sub.1-6 aliphatic-amino, R.sup.7 -sulfonyl, R.sup.7 sulfon |
| 6369086 |
Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhib |
April 9, 2002 |
| The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling |
| 6172064 |
Formamides as therapeutic agents |
January 9, 2001 |
| A family of compounds having the general structural formula ##STR1##where W is a reverse hydroxamic acid group, and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, bi |
| 6100273 |
Water soluble camptothecin derivatives |
August 8, 2000 |
| The present invention relates to water soluble, camptothecin derivatives of formula (I). ##STR1## wherein A represents a moiety of the formula (IIA), (IIB) or (IIC): ##STR2## X is selected from the group consisting of alkyl, aryl, (CH.sub.2).sub.m OR.sup.1, (CH.sub.2).sub.m SR.su |
| 6090825 |
Oxazole derivatives as antagonists of alpha 1C andrenergic receptors |
July 18, 2000 |
| Oxazole compounds having formula (I) wherein R.sup.1 and R.sup.3 are selected from the group consisting of hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkyl, phenyl or phenyl mono- or disubstituted with C.sub.1-6 alkyl, halogen, hydroxy, C.sub.1-6 alko |
